Long Noncoding RNA PVT1 Promotes EMT and Cell Proliferation and Migration Through Downregulating p21 in Pancreatic Cancer Cells

Technology in Cancer Research and Treatment

Volumn 16, Issue 6, 2017, Pages 819-827

  Wu, Bao Qiang ^a   Jiang, Yong ^a   Zhu, Feng ^a   Sun, Dong Lin ^a   He, Xiao Zhou ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

EMT; lncRNA; p21; pancreatic cancer; PVT1

Indexed keywords

LONG UNTRANSLATED RNA; PROTEIN P21; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1;

ADULT; ARTICLE; CELL CULTURE; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PANCREAS CANCER; PLASMACYTOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 85037118084     PISSN: 15330346     EISSN: 15330338     Source Type: Journal    
DOI: 10.1177/1533034617700559     Document Type: Article

References (28)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
2. Pericleous M, Rossi RE, Mandair D, Whyand T, Caplin M. Nutrition and pancreatic cancer. Anticancer Res. 2014;34(1):9–21.
3. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7.
4. Cheetham SW, Gruhl FJ, Mattick JS, Dinger ME. Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013;108(12):2419.
5. Zhang Y, Yan W, Jung YS, Chen X. PUMA cooperates with p21 to regulate mammary epithelial morphogenesis and epithelial-to-mesenchymal transition. PloS One. 2013;8(6):e66464.
6. Huang C, Yu W, Wang Q. Increased expression of the lncRNA PVT1 is associated with poor prognosis in pancreatic cancer patients. Minerva Med. 2015;106(3):143.
7. You L, Chang D, Du HZ, Zhao YP. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. Biochem Biophys Res Commun. 2011;407(1):1.
8. Cui D, Yu CH, Liu M, Xia Q, Zhang Y, Jiang W. Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer. Tumor Biol. 2015;37(3):4127.
9. Acloque H, Adams MS, Fishwick KJ, Bronnerfraser M, Nieto MA. Epithelial–mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009;119(6):1438.
10. Thiery JP. Epithelial–mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15(6):740–746.
11. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890.
12. Cano CE, Motoo Y, Iovanna JL. Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. Scientific World J. 2010;10:1947.
13. Bachman KE, Blair BG, Brenner K. p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther. 2004;3(2):221.
14. Hartland SN, Prost S. TGFbeta induces apoptosis and EMT in primary mouse hepatocytes independently of p53, p21 Cip1 or Rb status. BMC Cancer. 2008;8:191.
15. Xie Z, Chen X, Li J. Salivary HOTAIR and PVT1 as novel biomarkers for early pancreatic cancer. Oncotarget. 2016;7(18):25408–25419.
16. Kong R, Zhang EB, Yin DD. Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer. 2015;14:82.
17. Takahashi Y, Sawada G, Kurashige J. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer. 2014;110(1):164.
18. Guan Y, Kuo W, Stilwell JL. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res. 2007;13(19):5745–5755.
19. Zhuang C, Li J, Liu Y. Tetracycline-inducible shRNA targeting long non-coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells. Oncotarget. 2015;6(38):41194.
20. Walsh AL, Tuzova AV, Bolton E, Lynch TH, Perry AS. Long noncoding RNAs and prostate carcinogenesis: the missing ‘linc’? Trends Mol Med. 2014;20(8):428–436.
21. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400.
22. Zhai H, Fesler A, Schee K, Fodstad O, Flatmark K. Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer. Clin Colorectal Cancer. 2013;12(4):261–266.
23. Lo KWK, Yu MMY, Yim SF, Poon CS, Chung TKH, Wong YF. Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma. Cancer Lett. 2001;172(1):93.
24. Park J, Kim J, Park JK. Association of p21-activated kinase-1 activity with aggressive tumor behavior and poor prognosis of head and neck cancer. Head Neck. 2015;37(7):953–963.
25. Teramen H, Tsukuda K, Tanaka N. Aberrant methylation of p21 gene in lung cancer and malignant pleural mesothelioma. Acta Med Okayama. 2011;65(3):179.
26. Liu M, Casimiro MC, Wang C. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A. 2009;106(45):19035–19039.
27. Zhou Q, Chen J, Feng J, Wang J. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumor Biol. 2015;37(3):3105.
28. Wang F, Yuan J, Wang S. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology. 2014;60(4):1278–1290.